Aktis Oncology, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-22$22.40 RISE2026-03-27$15.19 PEAK2026-04-23$22.08 91d | -32.2% 64d | Missed | Missed | — | — | +45.4% 27d | Missed |
DROP2026-01-22$22.40 RISE2026-02-18$17.63 PEAK2026-04-23$22.08 91d | -21.3% 27d | Missed | Missed | — | — | +25.2% 64d | Missed |
No scored news yet for a sentiment trend.
What recent performance says about Aktis Oncology Aktis Oncology (AKTS) has drawn fresh attention after recent trading, with the stock up 6.4% on the day and 9.3% over the past week, even as it is down 4.3% over the past month. See our latest analysis for Aktis Oncology. For context, Aktis Oncology’s recent 1 day share price return of 6.38% and 7 day share price return of 9.30% come after a 30 day share price return that is down 4.33% and a year to date share price return that is down 9.20%...
Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026 ASCO Annual MeetingEnrolling patients with Nectin-4 expressing tumors in ongoing Phase 1b clinical trial of AKY-1189; expect preliminary data in first quarter 2027 BOS
Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.64 percent. This is a 97.96 percent increase over losses of $(18.60) per share from
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the BofA Securities Health Care Conference in Las Vegas, Nevada. The presentation will ta
Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate indication-specific data in metastatic castration-resistant prostate cancer (mCRPC) while also exploring broader po
Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate indication-specific data in metastatic castration-resistant prostate cancer (mCRPC) while also exploring broader po
AKY-2519 Clinical Development Strategy May 5, 2026 1 ...
Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid tumorsTwo-trial strategy enables evaluation of AKY-2519 in broader patient segments and efficient generation of indication-relevant data; preliminary mCRPC data expected in 2027 Aktis to hold conference call tomorrow, Tuesday, May 5, 2026, at 8 a.m. ET to discuss its clinical development strategy for AKY-2519 BOS
Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today announced the
Top analysts change outlook on Hyperfine Inc, Legence, and Aktis Oncology with Buy/Outperform ratings and price targets. See other analysts' views.
William Blair analyst Alexandra Ramsey initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating.
Aktis Oncology (AKTS) stock is given a "Buy" rating, driven by its innovative miniprotein radioconjugates targeting Nectin-4 and B7-H3 solid tumors. Read the full analysis here.
Key recent performance snapshot Aktis Oncology (AKTS) has drawn investor attention after a recent one-month return of about 40%, contrasting with a small decline over the past three months and a modest year-to-date loss. The clinical-stage company, focused on targeted radiopharmaceuticals for solid tumors, currently has a market value of about US$1.18 billion and last closed at US$21.26 per share. See our latest analysis for Aktis Oncology. For context, the recent 40% 1 month share price...
Key recent performance snapshot Aktis Oncology (AKTS) has drawn investor attention after a recent one-month return of about 40%, contrasting with a small decline over the past three months and a modest year-to-date loss. The clinical-stage company, focused on targeted radiopharmaceuticals for solid tumors, currently has a market value of about US$1.18 billion and last closed at US$21.26 per share. See our latest analysis for Aktis Oncology. For context, the recent 40% 1 month share price...
AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentationsData facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumors and normal tissues in patients with B7-H3 expressing solid tumorsPhase 1b clinical trial of AKY-2519 to start mid-2026 BOSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential o
Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed
The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AKTS | +6.80% | +3.70% | — | — |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.83% | +9.42% | — | — |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Wellington | fundamental | 2.32M | $41.45M | 0.01% | New | 2026-03-31 |
| StateStreet | passive | 428.3K | $7.66M | 0.00% | New | 2026-03-31 |
| FidelityFMR | fundamental | 386.4K | $6.91M | 0.00% | New | 2026-03-31 |
| Soros | macro | 100.0K | $1.79M | 0.02% | New | 2026-03-31 |
| DEShaw | quant | 17.1K | $305.24K | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 1.56M | $27.98K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.48 | — | — |
| 2026-05-11 | -0.35 | -0.38 | -8.57% |
| 2024-11-14 | -0.08 | -0.04 | +53.88% |
| 2024-10-08 | -0.14 | -0.75 | -435.71% |
| 2024-05-13 | -0.12 | -0.14 | -18.64% |
| 2024-02-13 | -0.18 | -0.19 | -5.56% |
| 2023-11-13 | -0.18 | -0.27 | -50.00% |
| 2023-09-06 | -0.18 | -0.21 | -16.67% |
| 2023-05-08 | -0.21 | -0.20 | +6.98% |
| 2023-02-07 | -0.25 | -0.19 | +25.49% |
| 2022-11-14 | -0.23 | -0.28 | -20.00% |
| 2022-09-12 | -0.21 | -0.26 | -20.93% |
| 2022-05-02 | -0.23 | -0.22 | +4.35% |
| 2022-01-31 | -0.23 | -0.23 | -1.47% |
| 2021-11-01 | -0.19 | -0.21 | -7.69% |
| 2021-08-30 | -0.17 | -0.19 | -8.57% |